While our results show that β-AR antagonists disrupt tumor cell function, the dramatic anti-tumor responses observed following administration of β-AR antagonists in angiosarcoma patients may also be due, at least in part, to effects on cells within the tumor stroma. The gene discussed is ADRB2; the disease is angiosarcoma.